lilly retatrutide Eli Reports Strong Late-Stage Results for Next-Generation Obesity Drug Lilly announces more next-gen obesity

In a 64-week clinical trial , the Wegovy pill resulted in an average weight loss of 13.6%, and in a 68-week clinical trial, the Wegovy injection produced an average weight loss of 14.9%

The net result: reduced appetite (GLP-1), improved insulin action and fat metabolism (GIP), plus increased energy expenditure (glucagon)

A popular medical treatment for obesity is a once-weekly injection of drugs that work to mimic glucagon-like peptide-1 (GLP-1)

For patients without that benefit, Curex offers compounded semaglutide from $49/mo (compounded tirzepatide from $149/mo) at getcurex.com/cl/glp no insurance, no prior authorization

Have Patience and Keep Motivated Even with exercise and a healthy diet, weight loss with GLP-1 doesnt decrease the pounds and shred the fat quickly

Fitty Tip: Craving something sweet